Home » China Updates Penalty, Inspection Regs in Wake of Pharma Industry Probe
China Updates Penalty, Inspection Regs in Wake of Pharma Industry Probe
October 8, 2013
The China Food and Drug Administration is asking the public to comment on proposed revisions to its regulations and penalties related to inspections and investigations, an apparent response to the ongoing bribery scandal that has rocked the pharmaceutical industry.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor